Moxifloxacin Ophthalmic Solution — Class II drug recall D-0101-2023
Terminated recall by Direct Rx, reported 2023-01-18, distributed in FL. cGMP deviation: discontinue of stability support for product.
| Recall number | D-0101-2023 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Direct Rx, Dawsonville, GA, United States |
| Recall initiated | 2022-11-02 |
| Classified | 2023-01-11 |
| Reported by FDA | 2023-01-18 |
| Terminated | 2024-09-30 |
| Distributed | FL |
| Quantity | 11 bottles |
| Reason classes | cgmp, specification failure |
| NDC | 72189-0334-05 |
| Lot numbers | 07MA2232 |
| Expiration dates | 2023-04-30 |
Product
Moxifloxacin Ophthalmic Solution, 0.5%, 3 mL, Rx Only, Packaged and Distributed By: Direct Rx, LLC 94 Worldwide Drive, Dawsonville, GA 30534, NDC 72189-0334-05
Reason for recall
cGMP deviation: discontinue of stability support for product.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0101-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.